Horizon Therapeutics announces acquisition by Amgen approved in Ireland

Horizon Therapeutics (HZNP) sanctioned the scheme of arrangement between Horizon and its shareholders under Chapter 1 of Part 9 of the Irish Companies Act 2014 pursuant to which Pillartree Limited, a private limited company wholly owned by Amgen (AMGN) will acquire the entire issued and to be issued ordinary share capital of Horizon. As set out in the definitive proxy statement filed by the company with the SEC on January 23, completion of the proposed transaction remains subject to the delivery to the Registrar of Companies in Ireland of a copy of the order of the court sanctioning the Scheme under section 453 of the Irish Companies Act 2014. Assuming that a copy of the order is processed and made available to Horizon by no later than the morning of October 6, the order is expected to be delivered to the registrar on October 6 and, accordingly, the scheme is expected to take effect on October 6. Certain capitalized words used in this announcement and not herein defined have the meanings given to such words in the Scheme set forth in Part 3 of the Proxy Statement.